However, similar to tocilizumab, blocking IL-1β signaling by anakinra may not completely treat inflammatory toxicities as IL-1R deficient mice also developed CRS symptoms following CAR-T cell infusion (65). Here, IL1R1 is linked to congenital rubella syndrome.